Viewing Study NCT05092269


Ignite Creation Date: 2025-12-24 @ 10:56 PM
Ignite Modification Date: 2025-12-28 @ 4:32 PM
Study NCT ID: NCT05092269
Status: RECRUITING
Last Update Posted: 2025-12-05
First Post: 2021-10-13
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Long-term Extension Study of Ustekinumab in Pediatric Participants
Sponsor: Janssen Research & Development, LLC
Organization:

Study Overview

Official Title: A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study of Ustekinumab in Pediatric Clinical Study Participants (2 to <18 Years of Age)
Status: RECRUITING
Status Verified Date: 2025-12
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: UNITED
Brief Summary: The purpose of this study is to collect long-term safety data of subcutaneous (SC) ustekinumab
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?:

Secondary ID Infos

Secondary ID Type Domain Link View
CNTO1275ISD3001 OTHER Janssen Research & Development, LLC View
2020-004457-76 EUDRACT_NUMBER None View
2022-501067-40-00 REGISTRY EUCT number View